Alle verbonden artikelen

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Auteurs : Goldhirsch A, Winer EP, Coates AS, Gelber Rd, Piccart-Gebhart M, Thürlimann B, Senn HJ
Jaar : 2013
Journal : Ann Oncol
Volume : 24(9)
Pagina's : 2206-23

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(2)
Pagina's : 273-82

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Auteurs : Partridge AH, Gelber S, Piccart-Gebhart M, Focant F, Scullion M, Holmes E, Winer EP, Gelber Rd
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(21)
Pagina's : 2692-8

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Auteurs : Martin M, Bonneterre J, Geyer CE, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Awada A
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(18)
Pagina's : 3763-72

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Auteurs : Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E
Jaar : 2013
Journal : Ann Oncol
Volume : 24(1)
Pagina's : 109-16

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Auteurs : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Jaar : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pagina's : 960-967

Luminal breast cancer: from biology to treatment.

Auteurs : Ignatiadis M, Sotiriou C
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pagina's : 494-506

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Auteurs : Vanderbeeken MC, Aftimos P, Awada A
Jaar : 2013
Journal : Current Breast Cancer Rep
Volume : 5
Pagina's : 31-41

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Jaar : 2013
Journal : Lancet
Volume : 382(9897)
Pagina's : 1021-8

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Auteurs : Vanderbeeken MC, de Azambuja E
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pagina's : 27-30

Why your preferred targeted drugs may become unaffordable.

Auteurs : Piccart-Gebhart M
Jaar : 2013
Journal : Cancer Res
Volume : 73(19)
Pagina's : 5849-51

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Jaar : 2013
Journal : J Clin Invest
Volume : 123(7)
Pagina's : 2873-92

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Auteurs : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pagina's : 2586-92

Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.

Auteurs : Maréchal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, Hendlisz A, Demols A, Franchimont D, Verset G, Van Houtte P, Van de Stadt J, Van Laethem JL
Jaar : 2012
Journal : Ann Oncol
Volume : 23(6)
Pagina's : 1525-30

The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer.

Auteurs : Mouton C, Ronson A, Razavi D, Delhaye F, Kupper N, Paesmans M, Moreau M, Nogaret JM, Hendlisz A, Gidron Y
Jaar : 2012
Journal : Auton Neurosci
Volume : 166(1-2)
Pagina's : 96-9

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Auteurs : Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M
Jaar : 2012
Journal : Med. Oncol.
Volume : 29(3)
Pagina's : 1896-1907

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

Auteurs : Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Maréchal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(3)
Pagina's : 570-6

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Auteurs : van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(23)
Pagina's : 2861-8

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Auteurs : De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(2)
Pagina's : 191-9

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Auteurs : Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart-Gebhart M, Sotiriou C, Loi S
Jaar : 2012
Journal : Clin Cancer Res
Volume : 18(5)
Pagina's : 1341-51